6.29
1.45%
0.09
시장 영업 전:
6.29
Mannkind Corp 주식(MNKD)의 최신 뉴스
MannKind's SWOT analysis: inhaled therapeutics firm's stock shows promise amid challenges - Investing.com
More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®) - GlobeNewswire Inc.
MannKind Co. (NASDAQ:MNKD) Shares Bought by Dark Forest Capital Management LP - MarketBeat
Mannkind Corp (MNKD)’s results reveal risk - US Post News
The Attractiveness of Investing In Mind Medicine Inc (MNMD) is Growing - Knox Daily
A new trading data show Mannkind Corp (MNKD) is showing positive returns. - SETE News
MNKD stock rated an Outperform by Leerink Partners - Knox Daily
Closing Figures: Mind Medicine Inc (MNMD)’s Negative Finish at 5.87, Down -1.68 - The Dwinnex
Manba Finance IPO Sees Stellar 73.18 Times Subscription on Second Day - Devdiscourse
Manba Finance IPO subscribed 73.18 times on Day 2 amid heavy demand from institutional investors - NewsDrum
Latest News - LatestLY
Mind Medicine Inc (MNMD) produces promising results - US Post News
Stock market update: Nifty Pharma index advances 0.23% - The Economic Times
Manba Finance IPO continues to attract great interest, subscribed 73 times on day 2 - Moneycontrol
Manba Finance IPO subscribed 56 times so far on Day 2 - Indiainfoline
Manba Finance IPO Day 2: Issue subscribed 41.11 times so far, check key dates and more - Upstox
Manaba Finance IPO Day 2: Check latest subscription, expected listing gains - India Today
Mankind Pharma To Raise Rs 7,000-Crore Debt For Bharat Serums Acquisition - NDTV Profit
Stock to buy today: Mankind Pharma (₹2,651.30): BUY - BusinessLine
Trade Spotlight: How should you trade Siemens, Mankind Pharma, Kotak Bank, DLF, Indegene and others on... - Moneycontrol
Avoro Capital Advisors LLC Reduces Stock Position in MannKind Co. (NASDAQ:MNKD) - MarketBeat
Manba Finance Limited IPO Subscribed 23.67 Times on Day 1 of Bidding, Sale To Conclude on September 25; - LatestLY
Manba Finance IPO subscribed 23.67 times on Day 1 - NewsDrum
Mankind Pharma announces ₹10,000 crore fundraise | Tap to know more | Inshorts - Inshorts
Pharma stock jumps 4% after company announces ₹ 10,000 Cr fundraise - Trade Brains
Mankind Pharma Announces NCD Fundraising Initiative - Indiainfoline
Mankind Pharma Ltd soars 3.76% - Business Standard
Mankind Pharma up 4% as board approves raising Rs 10,000-cr via NCDs, CPs - Business Standard
Mankind Pharma plans to repay debt taken for BSV acquisition within three years - CNBCTV18
Mankind Pharma Shares Hit Record High After Company Announces ₹10,000 Crore Fund Raising - Free Press Journal
Mankind Pharma Shares Hit Life High After Board Nod To Rs 10,000 Crore Fundraise - NDTV Profit
Mankind Pharma jumps to record high; gains 9% in two days after Investec's 'buy' tag - Moneycontrol
Fundamentally strong pharma stocks to buy now for an upside of 30% - Trade Brains
Mankind Pharma shares surge over 2% after board approves raising Rs 10,000 crore - Business Upturn
Manba Finance Raises ₹45.25 Crore from Anchor Investors Ahead of IPO - Indiainfoline
Stocks in focus on 23rd September: HDFC Bank, Mankind Pharma, BHEL, Tata Steel and more - Business Upturn
MannKind Co. (NASDAQ:MNKD) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Mankind Pharma board OKs to raise Rs 10,000 cr - Business Standard
MannKind Corporation (MNKD): Short Seller Sentiment is Bearish - Insider Monkey
MannKind Corporation (MNKD): Short Seller Sentiment is Bearish - Yahoo Finance
14 Worst 52-Week High Stocks to Buy According to Short Sellers - Insider Monkey
MNKD Shares Experience Surge in Value - Knox Daily
Mankind Pharma board approves raising Rs 10,000 crore through NCDs - The Economic Times
Riding the Waves: A Guide to Investing in MNKD Stock - The InvestChronicle
Mankind Pharma to raise up to ₹10,000 crore through NCDs - CNBCTV18
Mankind Pharma to raise funds up to Rs 10k crore via debt instruments - Business Standard
Broker’s call: Mankind Pharma (Buy) - BusinessLine
Mankind Pharma board gives nod to Rs 10,000 crore fundraise via bonds - MSN
Mankind Pharma board approves up to Rs 10,000-crore fund raise via NCDs, CPs - Moneycontrol
Mankind Pharma to raise up to Rs 10,000 crore through bonds - Zee Business
Mankind Pharma Board approves raising Rs 10,000 crore via NCDs and CPs - Business Upturn
India's Mankind Pharma hits record high after Investec sets Street-high price target - XM
Mankind Pharma shares surge to a record high after Investec projects 35% upside - CNBCTV18
Mankind up 7% ahead of board meet for fund raising; m-cap tops Rs 1 trn - Business Standard
Sensex Today Trades Higher | Nifty Above 25,450 | IIFL Finance Rallies 10%, Mankind Pharma Jumps 4% - Equitymaster
Mankind Pharma shares zoom 7% to new record high after Investec initiates coverage with 'buy' rating, sees 36% upside | Stock Market News - Mint
Mankind Pharma shares surge 5% after Investec initiates ‘Buy’ call - Business Upturn
Mankind Pharma stock rises 4% as Investec initiates with 'buy' - Moneycontrol
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Shares Acquired by Bank of New York Mellon Corp - MarketBeat
Mannkind Corp (MNKD) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
MannKind advances phase 3 NTM lung disease study - Investing.com
Mankind Pharma board to consider fund raising on Sep 20 - Business Standard
Mankind Pharma to consider fund raise on September 20 - Moneycontrol
Stocks To Watch: Infosys, Mankind Pharma, Ceigall India, REC, Torrent Power, ONGC And More - NDTV Profit
Mankind Pharma board to meet this week to consider fund raising - The Economic Times
Mankind Pharma Share Price Could Jump as Board Considering Fund Raising for Expansion - TopNews India
Mannkind Corp (MNKD) gets rating Resumed from Leerink Partners - Knox Daily
MannKind (NASDAQ:MNKD) Sets New 52-Week High at $6.50 - MarketBeat
Take off with Mannkind Corp (MNKD): Get ready for trading - SETE News
Insider’s View: Deciphering Mannkind Corp (MNKD)’s Financial Health Through Ratios - The Dwinnex
MannKind Corporation (MNKD): Short Seller Sentiment is Bearish on This Stock - Insider Monkey
MannKind Co. (NASDAQ:MNKD) Shares Purchased by Bank of New York Mellon Corp - MarketBeat
MNKD Stock: Exploring Mannkind Corp’s Growth - The InvestChronicle
10 Worst Cancer Stocks To Buy Now According to Short Sellers - Insider Monkey
자본화:
|
볼륨(24시간):